Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neurogene Inc. - Common Stock
(NQ:
NGNE
)
32.11
+0.62 (+1.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
48,817
Open
31.49
Bid (Size)
31.88 (1)
Ask (Size)
32.13 (4)
Prev. Close
31.49
Today's Range
31.06 - 32.93
52wk Range
12.49 - 53.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024
May 10, 2024
NGNE stock results show that Neurogene beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
May 10, 2024
From
Neurogene Inc.
Via
Business Wire
Performance
YTD
+61.60%
+61.60%
1 Month
+6.22%
+6.22%
3 Month
+6.50%
+6.50%
6 Month
+112.65%
+112.65%
1 Year
+112.65%
+112.65%
More News
Read More
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
May 07, 2024
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
April 22, 2024
From
Neurogene Inc.
Via
Business Wire
MicroMarvel Neurogene Challenges Big Pharma
January 22, 2024
Via
Talk Markets
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
April 12, 2024
Via
InvestorPlace
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
March 18, 2024
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
March 04, 2024
From
Neurogene Inc.
Via
Business Wire
Neurogene to Participate in Upcoming Investor Conferences
February 29, 2024
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
January 16, 2024
From
Neurogene Inc.
Via
Business Wire
Neurogene Announces Business Update and 2024 Outlook
January 05, 2024
From
Neurogene Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.